Fabienne A Biétry1,2, Alena M Pfeil3, Oliver Reich4, Matthias Schwenkglenks3, Christoph R Meier5,6. 1. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, Hospital Pharmacy, University of Basel, Spitalstrasse 26, 4031, Basel, Switzerland. 2. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. 3. Institute of Pharmaceutical Medicine (ECPM), University of Basel, Basel, Switzerland. 4. Department of Health Sciences, Helsana Insurance Group, Zürich, Switzerland. 5. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, Hospital Pharmacy, University of Basel, Spitalstrasse 26, 4031, Basel, Switzerland. christoph.meier@usb.ch. 6. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. christoph.meier@usb.ch.
Abstract
BACKGROUND: A possible association between benzodiazepine use and Alzheimer's disease (AD) has been hypothesized in previous studies. OBJECTIVES: Using claims data from the Helsana Group, a large Swiss health insurance provider, we examined the association between previous benzodiazepine use and the risk of AD. METHODS: We conducted a matched case-control study and identified 1438 incident AD cases between 2013 and 2014 based on recorded first-time use of drugs used to treat AD [i.e., acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the N-methyl-D-aspartate receptor antagonist memantine] and matched one control to each case on age, sex, index date, and residence (canton). Because the initiation of benzodiazepine use shortly before the AD diagnosis date may occur as a result of symptomatic treatment of prodromal symptoms of early major neurocognitive disorder, we introduced an induction period of 2 years before the AD diagnosis date. Additionally, we categorized medication use by duration of use prior to the index date using prescriptions. We applied conditional logistic regression analyses to calculate odds ratios with 95% confidence intervals and adjusted for use of antidepressants. RESULTS: The crude odds ratio (95% confidence interval) of developing AD for patients starting benzodiazepine treatment was 1.71 (1.17-2.99) in the year before diagnosis and 1.19 (0.82-1.72) in the third year before diagnosis. After accounting for benzodiazepine use initiated during the prodromal phase, benzodiazepine use was not associated with an increased risk of developing AD; long-term benzodiazepine use (≥30 prescriptions) yielded an adjusted odds ratio of 0.78 (0.53-1.14). CONCLUSIONS: After taking into consideration a possible protopathic bias in the 2 years preceding the AD diagnosis date, benzodiazepine use was not associated with an increased risk of developing AD.
BACKGROUND: A possible association between benzodiazepine use and Alzheimer's disease (AD) has been hypothesized in previous studies. OBJECTIVES: Using claims data from the Helsana Group, a large Swiss health insurance provider, we examined the association between previous benzodiazepine use and the risk of AD. METHODS: We conducted a matched case-control study and identified 1438 incident AD cases between 2013 and 2014 based on recorded first-time use of drugs used to treat AD [i.e., acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the N-methyl-D-aspartate receptor antagonist memantine] and matched one control to each case on age, sex, index date, and residence (canton). Because the initiation of benzodiazepine use shortly before the AD diagnosis date may occur as a result of symptomatic treatment of prodromal symptoms of early major neurocognitive disorder, we introduced an induction period of 2 years before the AD diagnosis date. Additionally, we categorized medication use by duration of use prior to the index date using prescriptions. We applied conditional logistic regression analyses to calculate odds ratios with 95% confidence intervals and adjusted for use of antidepressants. RESULTS: The crude odds ratio (95% confidence interval) of developing AD for patients starting benzodiazepine treatment was 1.71 (1.17-2.99) in the year before diagnosis and 1.19 (0.82-1.72) in the third year before diagnosis. After accounting for benzodiazepine use initiated during the prodromal phase, benzodiazepine use was not associated with an increased risk of developing AD; long-term benzodiazepine use (≥30 prescriptions) yielded an adjusted odds ratio of 0.78 (0.53-1.14). CONCLUSIONS: After taking into consideration a possible protopathic bias in the 2 years preceding the AD diagnosis date, benzodiazepine use was not associated with an increased risk of developing AD.
Authors: John Gallacher; Peter Elwood; Janet Pickering; Antony Bayer; Mark Fish; Yoav Ben-Shlomo Journal: J Epidemiol Community Health Date: 2011-10-27 Impact factor: 3.710
Authors: Florindo Stella; Márcia Radanovic; Márcio L F Balthazar; Paulo R Canineu; Leonardo C de Souza; Orestes V Forlenza Journal: Curr Opin Psychiatry Date: 2014-05 Impact factor: 4.741
Authors: Rajaa Lagnaoui; Bernard Bégaud; Nicholas Moore; Anicet Chaslerie; Annie Fourrier; Luc Letenneur; Jean François Dartigues; Yola Moride Journal: J Clin Epidemiol Date: 2002-03 Impact factor: 6.437
Authors: Edo Richard; Christiane Reitz; Lawrence H Honig; Nicole Schupf; Ming X Tang; Jennifer J Manly; Richard Mayeux; Devangere Devanand; José A Luchsinger Journal: JAMA Neurol Date: 2013-03-01 Impact factor: 18.302
Authors: Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues Journal: Ann Neurol Date: 2008-11 Impact factor: 10.422
Authors: Shelly L Gray; Sascha Dublin; Onchee Yu; Rod Walker; Melissa Anderson; Rebecca A Hubbard; Paul K Crane; Eric B Larson Journal: BMJ Date: 2016-02-02
Authors: Kathryn Richardson; George M Savva; Penelope J Boyd; Clare Aldus; Ian Maidment; Eduwin Pakpahan; Yoon K Loke; Antony Arthur; Nicholas Steel; Clive Ballard; Robert Howard; Chris Fox Journal: Health Technol Assess Date: 2021-01 Impact factor: 4.014
Authors: Rainer Rupprecht; Christian H Wetzel; Mario Dorostkar; Jochen Herms; Nathalie L Albert; Jens Schwarzbach; Michael Schumacher; Inga D Neumann Journal: Mol Psychiatry Date: 2022-04-20 Impact factor: 15.992
Authors: Kathryn Richardson; Katharina Mattishent; Yoon K Loke; Nicholas Steel; Chris Fox; Carlota M Grossi; Kathleen Bennett; Ian Maidment; Malaz Boustani; Fiona E Matthews; Phyo K Myint; Noll L Campbell; Carol Brayne; Louise Robinson; George M Savva Journal: Am J Epidemiol Date: 2019-07-01 Impact factor: 4.897
Authors: Xhyljeta Luta; Christophe Bagnoud; Mark Lambiris; Anne Decollogny; Yves Eggli; Marie-Annick Le Pogam; Pedro Marques-Vidal; Joachim Marti Journal: BMJ Open Date: 2020-01-06 Impact factor: 2.692